



Lotus Eye Hospital And Institute Limited

CIN No. : L85110TZ1997PLC007783

770/12, Avinashi Road, Civil Aerodrome Post, Coimbatore - 641 014

Tel : 0422 - 4229900, 4229999

R.S.PURAM

155B, East Periasamy Road, Near Chinthamani,
North Coimbatore, R S Puram, Coimbatore - 641 002
Ph 0422 - 4239900, 4239999

SARAVANAMPATTI

86/1, Site No 2, TRM Avenue, Sathy Road,
Saravanampatti, Coimbatore - 641 035
Ph 0422 - 2210021

E-mail : info@lotuseye.org

Website : www.lotuseye.org

August 12, 2025

BSE Limited PhirozeJeejeebhoy Towers Dalal Street Mumbai- 400001 Scrip Code: 532998	National Stock Exchange of India Limited 5th Floor, Exchange Plaza Bandra (East) Mumbai – 400 051 Scrip Code: LOTUSEYE
--	---

Dear Sir/Madam

Sub: Outcome of Board Meeting held on August 12th 2025

In terms of Regulation 30 read with Part A Schedule III of SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015, we wish to inform you that the Board of Directors of the Company at its meeting held on August 12, 2025 has transacted the following business:

- 1) Approved unaudited standalone results for the quarter and year ended June 30th 2025;

The Board meeting commenced by 04:45 pm ended by 05:35 PM

We request you to please take the same on your record.

Yours Faithfully

For Lotus Eye Hospital and Institute Limited

M Achuth Menon

Company secretary & Compliance Officer

Membership No – A63980

SALEM : 86, Brindhavan Road, Fairlands, Salem - 636 016. Ph : 0427 - 4219900, 4219999

TIRUPUR : 415, Kamaraj Road, Santhai Pettai Bus Stop, Thennampalayam, Palladam Road, Tiruppur - 641 604 Ph : 0421 - 4346060, 4219999

METTUPPALAYAM : No. 28, Coimbatore Main Rd, Opp Bus Stand, Mettupalayam - 634 301 Ph : 04254 - 223223, 224224

KOCHI : 533/33A-33F, Tejas Tower, SA Road, Kadavanthara, Kochi, Kerala - 682 020 Ph : 0484 - 2322333, 2322444

KOCHI : 229A, Kurisingal House, Mulanthuruty Post, Kochi, Kerala - 682 314 Ph : 0484 - 2743191, 2743121

KARUR : Door No 28, 2B/2, Sengunthapuram Main Road, Karur - 639002 Ph : 04324 459900, 74485 14851

LOTUS

Lotus Eye Hospital and Institute Limited

CIN: L85110TZ1997PLC007783

Registered office: 770/12, Avinashi road, Aerodrome post, Coimbatore 641 014


Phone no: 0422-4229900, Fax: 0422-4229933, E-mail: companysecretary@lotuseye.org, Website: www.lotuseye.org

Statement of Un-audited Financial Results for the Quarter ended June 30, 2025

(Rs. in lakhs)

Sr. No.	Particulars	Quarter Ended			Year Ended
		June 30, 2025	March 31, 2025	June 30, 2024	March 31, 2025
		(Un-audited)	(Audited)	(Un-audited)	(Audited)
	Income:				
I.	Revenue from operations	1,351.69	1,151.25	1,289.07	4,956.25
II.	Other income	18.76	50.99	30.61	130.13
III.	Total income (I+II)	1,370.45	1,202.24	1,319.68	5,086.38
IV.	Expenses:				
	(a) Cost of materials consumed	235.92	187.86	214.78	823.63
	(b) Purchase of stock-in-trade	184.20	163.92	202.24	740.44
	(c) Changes in inventories	(1.46)	25.38	(32.27)	(18.36)
	(d) Service expenses	261.20	240.77	225.47	944.60
	(e) Employee benefit expense	284.38	287.12	280.79	1,161.21
	(f) Finance costs	11.76	9.45	5.67	35.50
	(g) Depreciation and amortization expense	81.89	(58.23)	105.66	300.68
	(h) Other expenses	239.85	262.77	231.66	961.40
	Total expenses (IV)	1,297.74	1,119.04	1,234.00	4,949.10
V.	Profit/(loss) before exceptional items and tax (III-IV)	72.71	83.20	85.68	137.28
VI.	Exceptional items	0.27	1.00	(0.04)	0.98
VII.	Profit/(loss) before tax (V+VI)	72.98	84.20	85.64	138.26
VIII.	Tax expenses				
	(a) Current tax	14.31	12.88	23.60	36.34
	(b) Deferred tax	4.19	46.09	(0.30)	27.99
	Total tax expense (VIII)	18.50	58.97	23.30	64.33
IX.	Net profit/(loss) for the period (VII-VIII)	54.48	25.23	62.34	73.93
X.	Other comprehensive income, net of income tax				
	A. Items that will not be reclassified to profit or loss				
	- Remeasurement of post-employment defined benefit plan	(3.00)	(14.53)	(2.00)	(20.53)
	- Income tax on the above item	0.83	4.04	0.56	5.71
	B. Items that will be reclassified to profit or loss	-	-	-	-
	Total other comprehensive income, net of income tax (X)	(2.17)	(10.49)	(1.44)	(14.82)
XI.	Total comprehensive income for the period (IX + X)	52.31	14.74	60.90	59.11
XII.	Paid-up equity share capital (face value of Rs. 10/- each)	2,079.63	2,079.63	2,079.63	2,079.63
XIII.	Earning per equity share: (of Rs. 10/-) (Not annualised)				
	(1) Basic (In Rs.)	0.26	0.12	0.30	0.36
	(2) Diluted (In Rs.)	0.26	0.12	0.30	0.36

For Lotus Eye Hospital & Institute Limited



 Ms. S. SANGEETHA
 (Managing Director - DIN : 01859252)

Notes :

1. The above unaudited financial results have been reviewed by the Audit committee and the same has been approved by the Board of Directors at their meeting held on 12th August, 2025. The statutory auditors have conducted a limited review of the financial results.
2. Exceptional items represent the profit/(loss) on sale of property, plant & equipment.
3. The figures for the quarter ended March 31, 2025 are the balancing figures between the audited figures in respect of the full financial year and the year-to-date figures upto third quarter of the respective financial years, which were subject to limited review by the Statutory auditors.
4. Figures of the previous period/ year have been regrouped / rearranged wherever necessary to conform to the current period / year presentation.

Coimbatore,
August 12, 2025.

For Lotus Eye Hospital & Institute Limited



Ms. S. SANGEETHA
Managing Director - DIN : 01859252


To
The Board of Directors,
Lotus Eye Hospital and Institute Limited,
Coimbatore.

Limited review report for the Quarter/Three months ended June 30, 2025

1. We have reviewed the accompanying statement of unaudited financial results of Lotus Eye Hospital and Institute Limited ("the Company") for the quarter/three months ended June 30, 2025, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended.
2. This statement which is the responsibility of the Company's management and approved by the Board of Directors at their meeting on August 12, 2025, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.
3. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with the aforesaid Indian Accounting Standards and other recognized accounting practices and policies, have not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Coimbatore,
August 12, 2025.

For Anbarasu & Jalapathi
Chartered Accountants
Firm Registration No.: 0107955



CA. K. Jalapathi
Partner

Membership No.: 214823

UDIN: 25214823BMUKAR6616